• Definium Therapeutics reported results from a healthcare claims study in CNS Spectrums showing high switching, discontinuation, and care gaps in GAD pharmacotherapy.
• 55% of newly diagnosed patients stopped initial therapy; 28% added or switched. Median discontinuation: 84 days, below 6-12 months guideline duration.
• Established patients showed 16% discontinuation; 55% added or switched. Median discontinuation: 119 days.
• 57% of newly diagnosed patients who discontinued did not restart during follow-up; median treatment gap for restarters was 146 days.
• Findings cited as evidence of unmet need for new GAD treatments with faster onset, sustained control, and improved tolerability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260714945154) on July 14, 2026, and is solely responsible for the information contained therein.